GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030949 describes any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor (VEGFR) signaling pathway activity.
• VEGFR signaling is positively regulated by ligands such as VEGF-A and VEGF-B, co-receptors like neuropilin-1, and soluble decoy receptors such as sVEGFR1 that modulate ligand availability.
• Positive regulation of VEGFR signaling is central to angiogenesis, vascular permeability, and immune modulation in tumors and metabolic diseases.
• Key genes include VEGFA, VEGFB, KDR (VEGFR2), FLT1 (VEGFR1), NRP1, and downstream effectors such as STAT3 and PD-L1.
• Dysregulated positive regulation of VEGFR signaling contributes to glioblastoma, lung cancer, diabetic kidney disease, and resistance to anti-angiogenic therapy.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of positive regulators within this pathway.
Description
The Gene Ontology term GO:0030949, positive regulation of vascular endothelial growth factor receptor signaling pathway, refers to any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity. This term captures the upstream and intracellular events that amplify VEGFR-dependent signals, which are essential for angiogenesis, vascular permeability, and immune cell crosstalk in both physiological and pathological contexts. Researchers study this process to understand how tumors, metabolic tissues, and immune cells hijack VEGFR signaling for growth, survival, and immune evasion. Because VEGFR signaling is frequently dysregulated in cancer and diabetic kidney disease, identifying positive regulators within this pathway is a major focus of translational research. Experimental models that manipulate these regulators, such as CRISPR knockout or overexpression, are critical for establishing causality and for developing targeted therapies.
positive regulation of vascular endothelial growth factor receptor signaling pathway At A Glance
| GO ID | GO:0030949 |
|---|---|
| GO term | positive regulation of vascular endothelial growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of vascular endothelial growth factor receptor signaling pathway; positive regulation of VEGF receptor signaling pathway; stimulation of vascular endothelial growth factor receptor signaling pathway; upregulation of vascular endothelial growth factor receptor signaling pathway |
| Major function | Enhances VEGFR-mediated signal transduction, promoting angiogenesis, vascular permeability, and immune modulation |
| Key ligands | VEGF-A, VEGF-B, and other VEGFR-binding factors |
| Key receptors | VEGFR1 (FLT1), VEGFR2 (KDR), and co-receptor NRP1 |
| Downstream effectors | STAT3, PD-L1, and adherens junction components |
| Disease relevance | Cancer, diabetic kidney disease, and immune evasion |
What Is GO:0030949?
In our own words, GO:0030949 encompasses all molecular events that enhance or sustain signaling downstream of vascular endothelial growth factor receptors (VEGFRs). This includes increased ligand availability (e.g., VEGF-A, VEGF-B), receptor dimerization and autophosphorylation, co-receptor engagement (e.g., neuropilin-1), and amplification of downstream kinase cascades. The term is distinct from the VEGFR signaling pathway itself (GO:0048010) because it specifically describes positive regulatory inputs that elevate the pathway's activity.
Why Is positive regulation of vascular endothelial growth factor receptor signaling pathway Important in Cell Biology?
Positive regulation of VEGFR signaling is a double-edged sword: it is required for normal vascular development and tissue repair, but its excessive activation drives pathological angiogenesis, vascular leak, and immune suppression in tumors and metabolic disorders. Understanding the positive regulators of this pathway provides mechanistic insight into how cancers resist anti-angiogenic therapies and how metabolic tissues crosstalk via VEGF-B. Moreover, VEGFR signaling intersects with immune checkpoints such as PD-L1, making it a nexus for combination immunotherapy strategies.
• Drives tumor angiogenesis and vascular permeability, supporting cancer growth and metastasis.
• Modulates immune checkpoints such as PD-L1 on tumor and immune cells, contributing to immune evasion.
• Mediates VEGF-B-dependent fatty acid flux in the adipose-kidney axis, linking to diabetic kidney disease.
• Regulates endothelial adherens junctions and vascular permeability through neuropilin-1.
• Serves as a biomarker for response to anti-angiogenic therapy combined with PD-1 blockade in NSCLC.
• Provides targets for CRISPR-based functional genomics to identify novel positive regulators.
• Involved in glioblastoma-educated macrophage crosstalk via PD-L1 and soluble VEGFR1.
• Offers mechanistic insights into resistance to VEGFR2 inhibitors like apatinib.
• Connects microbial metabolite sensing by microglia to astrocyte responses, with implications for neuroinflammation.
• Enables development of cell models for high-throughput screening of VEGFR pathway modulators.
What Happens During positive regulation of vascular endothelial growth factor receptor signaling pathway?
Ligand availability and receptor engagement
In simple terms: More VEGF ligand around means more receptor activation.
Positive regulation begins with increased availability of VEGFR ligands such as VEGF-A and VEGF-B, which bind to VEGFR1 and VEGFR2 on endothelial and other cells. Soluble VEGFR1 (sVEGFR1) can act as a decoy receptor, but its interaction with PD-L1 in glioblastoma-educated macrophages illustrates context-dependent positive regulation. Neuropilin-1 (NRP1) acts as a co-receptor that enhances VEGF binding to VEGFR2, thereby amplifying signaling.
Receptor dimerization and autophosphorylation
In simple terms: When VEGF binds, receptors pair up and activate each other.
Upon ligand binding, VEGFR2 undergoes dimerization and autophosphorylation, creating docking sites for downstream signaling proteins. This step is positively regulated by co-receptors and by intracellular scaffolds that stabilize the active receptor complex. The balance between membrane-bound and soluble VEGFR1 isoforms further modulates the intensity of receptor activation.
Downstream kinase cascade amplification
In simple terms: Activated receptors turn on a chain of signaling proteins that boost the response.
Phosphorylated VEGFR2 recruits and activates PLCγ, PI3K, and STAT3, leading to endothelial cell proliferation, migration, and survival. In lung cancer, apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 signaling, demonstrating that positive regulation of this axis can be targeted. The ROS/Nrf2/p62 pathway also intersects with VEGFR2 signaling to modulate cell fate.
Crosstalk with immune checkpoints
In simple terms: VEGF signaling can turn up immune brakes on T cells.
VEGF-A modulates the expression of inhibitory checkpoints on CD8+ T cells, thereby suppressing anti-tumor immunity. In glioblastoma, PD-L1 on macrophages interacts with soluble VEGFR1, linking VEGFR signaling to immune evasion. This crosstalk is a key mechanism by which positive regulation of VEGFR signaling promotes tumor progression.
Vascular permeability and adherens junction regulation
In simple terms: VEGF signaling can loosen the junctions between endothelial cells, making vessels leaky.
Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions, a process that is positively regulated by VEGFR signaling. This permeability is essential for immune cell extravasation but also contributes to edema and tumor metastasis.
Key Genes Involved in GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway
The following genes and proteins are central to the positive regulation of VEGFR signaling, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary ligand for VEGFR2; promotes angiogenesis and immune modulation | Target for anti-angiogenic therapy and immune checkpoint studies |
| VEGFB | Ligand for VEGFR1; regulates fatty acid flux in adipose-kidney axis | Linked to diabetic kidney disease and metabolic crosstalk |
| KDR (VEGFR2) | Main signaling receptor for VEGF-A; drives endothelial proliferation and permeability | Key target for inhibitors like apatinib; CRISPR KO models available |
| FLT1 (VEGFR1) | Receptor for VEGF-A/B; soluble isoform acts as decoy | Modulates ligand availability; implicated in glioblastoma immune evasion |
| NRP1 | Co-receptor enhancing VEGF binding to VEGFR2; regulates adherens junctions | Controls vascular permeability; potential target for edema |
| STAT3 | Downstream transcription factor activated by VEGFR2 | Mediates PD-L1 expression and autophagy in lung cancer |
| PD-L1 (CD274) | Immune checkpoint upregulated by VEGF signaling | Links VEGFR pathway to immune evasion; combination therapy target |
| Nrf2 (NFE2L2) | Redox-sensitive transcription factor intersecting with VEGFR2 signaling | Modulates oxidative stress response in cancer cells |
| p62 (SQSTM1) | Autophagy adaptor involved in VEGFR2/ROS signaling | Marker of autophagic cell death in lung cancer |
| sVEGFR1 | Soluble decoy receptor for VEGF; interacts with PD-L1 | Modulates ligand availability in tumor microenvironment |
| HIF1A | Hypoxia-inducible factor upstream of VEGFA | Drives VEGF expression under hypoxia; metabolic disease link |
| PI3K | Downstream kinase in VEGFR2 signaling | Mediates survival and migration signals |
| PLCγ | Downstream effector of VEGFR2 | Regulates endothelial proliferation |
| CD8+ T cells | Immune cells whose checkpoints are modulated by VEGF-A | Target for immunotherapy combination |
| Macrophages | Immune cells that interact with PD-L1 and sVEGFR1 in glioblastoma | Model for tumor-associated macrophage studies |
| Astrocytes | Respond to microglial signals involving VEGFR pathway | Neuroinflammation models |
How Is positive regulation of vascular endothelial growth factor receptor signaling pathway Regulated?
Positive regulation of VEGFR signaling is itself controlled by multiple feedback loops. Soluble VEGFR1 acts as a decoy to sequester VEGF ligands, thereby limiting pathway activation. In glioblastoma, PD-L1 on macrophages interacts with soluble VEGFR1, illustrating a checkpoint-mediated layer of regulation. Additionally, microbial metabolites can modulate microglial control of astrocytes, indirectly influencing VEGFR-related signaling in the central nervous system. These regulatory mechanisms ensure that VEGFR signaling is tightly controlled in normal tissues but can be hijacked in disease.
positive regulation of vascular endothelial growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KDR (VEGFR2) | Lung cancer; angiogenesis | CRISPR knockout in lung cancer cell lines |
| VEGFB | Diabetic kidney disease; lipotoxicity | Knockout mouse models for metabolic studies |
| PD-L1 (CD274) | Glioblastoma; immune evasion | Overexpression in macrophages |
| NRP1 | Vascular permeability disorders | Endothelial cell-specific knockout |
| VEGFA | Tumor immune suppression | Conditional knockout in tumor models |
Cancer and tumor angiogenesis
Positive regulation of VEGFR signaling is a hallmark of tumor angiogenesis. In lung cancer, apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling, demonstrating the therapeutic potential of targeting this pathway. VEGF-A modulates inhibitory checkpoints on CD8+ T cells, contributing to immune evasion. In glioblastoma, PD-L1 on macrophages interacts with soluble VEGFR1, linking VEGFR signaling to immune suppression. scRNA-seq has revealed that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade in non-small cell lung cancer.
Diabetic kidney disease
VEGF-B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease, highlighting a metabolic role for positive regulation of VEGFR signaling. This suggests that targeting VEGFR1 or its ligands could ameliorate renal lipotoxicity.
Neuroinflammation and glial crosstalk
Microglial control of astrocytes in response to microbial metabolites involves signaling pathways that intersect with VEGFR regulation, as shown in studies of the aryl hydrocarbon receptor. This indicates a broader role for VEGFR signaling in neuroinflammatory processes.
Vascular permeability disorders
Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions, a process positively regulated by VEGFR signaling. Dysregulation of this mechanism can lead to edema and vascular leak in various diseases.
From positive regulation of vascular endothelial growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does KDR knockout reduce tumor angiogenesis? | CRISPR knockout in endothelial cells |
| Does a point mutation in FLT1 alter ligand binding? | Point mutation knock-in in cell lines |
| Can NRP1 overexpression increase vascular permeability? | Overexpression in endothelial cells |
| Does VEGFB knockout ameliorate diabetic kidney disease? | Knockout mouse model |
| Does PD-L1 knock-in in macrophages affect T cell activity? | Knock-in in macrophage cell lines |
| Can tagged VEGFR2 track receptor trafficking? | Tagged knock-in in endothelial cells |
How to Study the positive regulation of vascular endothelial growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on VEGFR signaling | Identify positive regulators |
| Phosphoproteomics | Receptor and downstream phosphorylation | Quantify pathway activation |
| scRNA-seq | Cell-type-specific signaling responses | Tumor heterogeneity |
| Permeability assays | Endothelial barrier function | Vascular leak studies |
| Co-immunoprecipitation | Protein-protein interactions | Receptor complex assembly |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
| Flow cytometry | Immune checkpoint expression | PD-L1 modulation |
| ELISA | Soluble factor levels | sVEGFR1 and VEGF quantification |
CRISPR screening for positive regulators
Genome-wide CRISPR knockout or activation screens can identify novel positive regulators of VEGFR signaling. For example, scRNA-seq has revealed that VEGF signaling mediates response to anlotinib plus PD-1 blockade, suggesting that CRISPR screens could uncover resistance mechanisms.
Phosphoproteomics and signaling analysis
Phosphoproteomics can quantify VEGFR2 autophosphorylation and downstream kinase activation. Studies on apatinib-treated lung cancer cells have used such approaches to link VEGFR2/STAT3/PD-L1 signaling to autophagy and apoptosis.
Single-cell RNA sequencing
scRNA-seq enables dissection of VEGF signaling heterogeneity in tumors. It has been used to show that VEGF signaling mediates response to neoadjuvant anlotinib combined with PD-1 blockade in NSCLC.
Vascular permeability assays
In vitro and in vivo permeability assays, such as transendothelial electrical resistance and Miles assay, can measure the functional impact of positive regulators like neuropilin-1 on adherens junctions.
How CRISPR Can Be Used to Study GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway
Knockout
CRISPR knockout of KDR (VEGFR2) or FLT1 (VEGFR1) can abolish positive regulation of VEGFR signaling, providing causal evidence for their roles in angiogenesis and disease. Knockout of NRP1 in endothelial cells reduces vascular permeability, confirming its positive regulatory function.
Point Mutation
Point mutations in the kinase domain of VEGFR2 can be introduced to dissect specific phosphorylation sites required for downstream STAT3 activation. Such models help distinguish between signaling branches.
Knock-in
Knock-in of tagged VEGFR2 (e.g., GFP or HA) allows real-time tracking of receptor trafficking and dimerization in live cells. Knock-in of PD-L1 into macrophages can model glioblastoma immune evasion.
Overexpression
Overexpression of VEGFA or VEGFB in cell lines or mice can amplify positive regulation of VEGFR signaling, mimicking pathological states such as tumor angiogenesis or diabetic kidney disease. Overexpression of NRP1 enhances VEGF binding and permeability.
How EDITGENE Supports positive regulation of vascular endothelial growth factor receptor signaling pathway Research
Researchers studying positive regulation of vascular endothelial growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, immune modulation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of vascular endothelial growth factor receptor signaling pathway research.
Frequently Asked Questions About positive regulation of vascular endothelial growth factor receptor signaling pathway
What is GO:0030949?
GO:0030949 is the Gene Ontology term for positive regulation of vascular endothelial growth factor receptor signaling pathway, describing any process that activates or increases VEGFR signaling activity.
What genes are involved in positive regulation of VEGFR signaling?
Key genes include VEGFA, VEGFB, KDR (VEGFR2), FLT1 (VEGFR1), NRP1, STAT3, and PD-L1.
How does VEGF-A modulate immune checkpoints?
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors, contributing to immune evasion.
What is the role of neuropilin-1 in VEGFR signaling?
Neuropilin-1 acts as a co-receptor that enhances VEGF binding to VEGFR2 and controls vascular permeability through adherens junctions.
How is VEGFR signaling linked to diabetic kidney disease?
VEGF-B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
What experimental models are used to study VEGFR signaling?
CRISPR knockout, point mutation, knock-in, overexpression cell models, and mouse models are commonly used.
What is the connection between VEGFR2 and STAT3?
Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 signaling in lung cancer.
How does soluble VEGFR1 regulate VEGFR signaling?
Soluble VEGFR1 acts as a decoy receptor for VEGF ligands and interacts with PD-L1 in glioblastoma-educated macrophages.
Can CRISPR screening identify new VEGFR pathway regulators?
Yes, scRNA-seq and CRISPR screens have revealed VEGF signaling mediators of response to anlotinib plus PD-1 blockade in NSCLC.
What diseases involve dysregulated VEGFR signaling?
Cancer, diabetic kidney disease, and neuroinflammatory conditions involve dysregulated VEGFR signaling.
Conclusion
GO:0030949, positive regulation of vascular endothelial growth factor receptor signaling pathway, is a critical biological process that amplifies VEGFR signaling to drive angiogenesis, immune modulation, and metabolic crosstalk. Its dysregulation is implicated in cancer, diabetic kidney disease, and neuroinflammation, making it a prime target for therapeutic intervention. CRISPR-based models are indispensable for dissecting the causal roles of individual genes within this pathway, and EDITGENE offers the tools to accelerate such research.
References
- 1. Liu X et al.. 2023. Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.. BMC Cancer 23(1):259 PMID: 36941554
- 2. Rothhammer V et al.. 2018. Microglial control of astrocytes in response to microbial metabolites.. Nature 557(7707):724-728 PMID: 29769726
- 3. Xie C et al.. 2021. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.. J Exp Clin Cancer Res 40(1):266 PMID: 34429133
- 4. Folestad E et al.. 2025. Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.. Kidney Int 107(3):492-507 PMID: 39689809
- 5. Voron T et al.. 2015. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.. J Exp Med 212(2):139-48 PMID: 25601652
- 6. Failla CM et al.. 2018. Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1.. Int J Mol Sci 19(5) PMID: 29702562
- 7. Huang Z et al.. 2025. scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer.. J Transl Med 23(1):478 PMID: 40281576
- 8. Pal S et al.. 2024. Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions.. Angiogenesis 28(1):7 PMID: 39668325
